Evaluation of the new heterogeneous ACMIA immunoassay for the determination of whole-blood cyclosporine concentrations in bone marrow, kidney, heart, and liver transplant recipients

Transplant Proc. 2004 Jun;36(5):1317-20. doi: 10.1016/j.transproceed.2004.05.062.

Abstract

Cyclosporine (CyA) has a narrow therapeutic index. Determination of CyA concentrations correlate with rejection or adverse effects like nephropathy. Cyclosporine is assayed based on either chromatographic or many different immunoenzymologic techniques. The investigators evaluated a new heterogeneous immunoassay of CyA on RxL Dimension. The pretreatment step is automatically performed in the apparatus. Linearity, intra- and interday precision, limit of quantification, dilutions, and stability of the equipment were compared with the EMIT method for patient determinations. The heterogeneous immunoassay showed a good linearity between 0 and 500 ng/mL, and intra- and inter-day precision with a coefficient of variation below 9.2%. The investigators observed reproducible and accurate dilutions of high concentrations (500 to 2000 ng/mL). The correlation with the EMIT technique was valid: ACMIA = 0.964 EMIT + 0.156 (r = .96) for different types of transplant (n = 116). Finally, this new system improves the determination of CyA concentrations.

Publication types

  • Comparative Study

MeSH terms

  • Bone Marrow Transplantation / immunology*
  • Cyclosporine / blood*
  • Drug Monitoring / methods
  • Enzyme Multiplied Immunoassay Technique
  • Heart Transplantation / immunology*
  • Humans
  • Immunoassay / methods
  • Immunosuppressive Agents / blood
  • Kidney Transplantation / immunology*
  • Liver Transplantation / immunology*
  • Regression Analysis
  • Reproducibility of Results
  • Sensitivity and Specificity

Substances

  • Immunosuppressive Agents
  • Cyclosporine